Cost-effectiveness (CE) analysis of pembrolizumab as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States (US).

被引：0
|
作者：
Ramakrishnan, Karthik
Jain, Disha
Gandhi, Jyotika
Chirovsky, Diana Romana
Borse, Rebekah
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] CHEORS, N Wales, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e18013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18013
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States
    Borse, Rebekah H.
    Ramakrishnan, Karthik
    Gandhi, Jyotika
    Dhankhar, Praveen
    Chirovsky, Diana
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 954 - 965
  • [2] Network meta-analysis (NMA) of pembrolizumab for first-line (1L) treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Ramakrishnan, Karthik
    Mojebi, Ali
    Ayers, Dieter
    Chirovsky, Diana Romana
    Borse, Rebekah
    Keeping, Sam
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] REAL-WORLD OVERALL SURVIVAL AMONG PATIENTS RECEIVING FIRST-LINE (1L) PEMBROLIZUMAB IN THE TREATMENT OF RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) IN THE UNITED STATES
    Black, Christopher
    Wang, Liya
    Ramakrishnan, Karthik
    Hair, Gleicy
    Goto, Daisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A831 - A831
  • [4] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA IN COLOMBIA
    Urrego-Reyes, J.
    Lopez, C.
    Marrugo, A. C.
    Wurcel, V
    Khandelwal, A.
    Patel, A.
    Black, C.
    VALUE IN HEALTH, 2023, 26 (06) : S95 - S95
  • [5] Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
    Victoria Wurcel
    Diana Chirovsky
    Rebekah Borse
    Juan Ignacio Altuna
    Fernando Carabajal
    Jyotika Gandhi
    Advances in Therapy, 2021, 38 : 2613 - 2630
  • [6] Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
    Wurcel, Victoria
    Chirovsky, Diana
    Borse, Rebekah
    Altuna, Juan Ignacio
    Carabajal, Fernando
    Gandhi, Jyotika
    ADVANCES IN THERAPY, 2021, 38 (05) : 2613 - 2630
  • [7] Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.
    Fayette, Jerome
    Clatot, Florian
    Brana, Irene
    Saada, Esma
    van Herpen, Carla M. L. -
    Mazard, Thibault
    Perez, Cesar Augusto
    Tabernero, Josep
    Le Tourneau, Christophe
    Hollebecque, Antoine
    Arrula, Virginia Arrazubi
    Fontana, Elisa
    Kato, Shumei
    Sacco, Assuntina G.
    Harandi, Amir
    De Boer, J. P.
    Hellyer, Jessica
    Pennella, Eduardo
    Joe, Andrew K.
    Daste, Amaury
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States
    Liu, Maobai
    Han, Sijie
    Zheng, Bin
    Cai, Hongfu
    Yang, Jing
    Zhuang, Qian
    Li, Na
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9483 - 9493
  • [9] REAL-WORLD TREATMENT PATTERNS AND SURVIVAL WITH FIRST-LINE (1L) PEMBROLIZUMAB plus PLATINUM plus TAXANE THERAPY FOR PATIENTS WITH RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) IN THE UNITED STATES
    Black, C.
    Hanna, G. J.
    Wang, L.
    Ramakrishnan, K.
    Hair, G.
    Zheng, D.
    Goto, D.
    VALUE IN HEALTH, 2023, 26 (06) : S18 - S18
  • [10] Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
    Yeh, Justin
    Guddati, Achuta Kumar
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (06): : 1821 - 1826
12345